Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M)
Arcus Biosciences (RCUS) Form 10-Q / 10-K
Latest, FY2025
11
Period ended Dec 31, 2025
Change on a year earlier
-45.0%
20 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | -45.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| FY2024 | Dec 31, 2024 | 20 | -47.4% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 38 | -2.6% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 39 | -94.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 745 | +67,627.3% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 1.10 | +1,000.0% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 0.10 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_contract_asset
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.